Block listing Interim Review
1 June 2023 15:05 BST
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
(Note: Italicised terms have the same meaning as given in the Listing Rules.)
Date: 1 June 2023
| Name of applicant: | ASTRAZENECA PLC |
|||
| Name of scheme: | ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME |
|||
| Period of return: | From: | 1 DECEMBER 2022 | To: | 31 MAY 2023 |
| Balance of unallotted securities under scheme(s) from previous return: | 4,818,134 |
|||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 |
|||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 341,752 |
|||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 4,476,382 |
|||
| Name of contact: | Hannah Tattersall |
| Telephone number of contact: | +44 (0)746 498 2582 |
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.